Skip to content
etf.net

BBP

GradeANew York Stock Exchange Arca

Virtus Biotech ETF

Virtus · Inception 2014-12-16

$104.02−3.64 (−3.38%)

As of Sep 23, 2026, 2:19 PM EDT

Intraday session: down, 47 prints from 107.66 to 104.02. Range 104.02 to 107.89. Use the arrow keys to read each point.$105.00$106.00$107.00$108.0010 AM12 PM2 PM4 PM
Expense ratio
0.34%
Fund size
$106M
1Y return
+53.8%
Yield · Last 12 months
Data unavailable
Holdings
198
Volume · 30D
0M sh
NAV per share
$101.28
52W range
low $66.55high $105.21

The ETF.net BBP Grade

A

71/ 100

Confidence Medium

Six-pillar profile for BBP. Scores out of 100: Cost 92, Risk 59, Mission 83, Tradability 24, Holdings 82, Durability 49. Strongest: Cost (92). Weakest: Tradability (24). Leans toward Cost.
F< 25
D≥ 25
C≥ 40
B≥ 55
A≥ 70

Score 71 of 100 sits in the A band. Bands: A ≥ 70, B ≥ 55, C ≥ 40, D ≥ 25, F < 25; the scale skips E.

  • Cost

    What you pay to own it — the expense ratio plus trading frictions, ranked within its category.
    AScore 92
    —

  • Mission

    How faithfully it does the job it claims — tracking its mandate or index with minimal slippage.
    AScore 83
    —

  • Risk

    How violently it can move — volatility, drawdown depth, and downside capture versus its category.
    BScore 59
    —

  • Tradability

    How cheaply and easily you can get in and out — liquidity, spread, and premium/discount stability.
    FScore 24
    —

  • Holdings

    What it actually owns — the quality, breadth, and concentration of the underlying portfolio.
    AScore 82
    —

  • Durability

    Whether it will still be here — the fund’s assets, age, flows, and issuer staying power.
    CScore 49
    —

Graded as of Aug 18, 2026

Our read on BBP

ETF.net Research

ABiotech, minus the coin flips. BBP tracks an index of US-listed biotech companies that already have at least one FDA-approved therapy, so the basket leans commercial-stage instead of clinical-trial hopefuls.

Stated mandate

The fund seeks to track the LifeSci Biotechnology Products Index, which consists of U.S.-listed biotechnology stocks with at least one FDA-approved drug therapy.

Why people hold it

  1. 01The screen does the heavy lifting: index membership requires at least one FDA-approved drug therapy, which filters out pre-approval story stocks.
  2. 020.34% a year undercuts the biotech cohort median of 0.50% and sits below IBB's 0.44%.
  3. 03Running since 2014 and spread across roughly 200 US-listed names, so one approval or rejection does not decide the whole basket.
  4. 04One of the stronger builds in its biotech and genomics peer group, with a portfolio that stays close to the index it promises.

Worth knowing

  1. 01Thinly traded and modest in size next to the category's household names. Spreads can widen, which makes limit orders the safer habit.
  2. 02Income is not the point here. The fund has not been paying distributions, so the return story is price.
  3. 03An approved drug filters risk, it does not erase it. This is a single-sector biotech basket, and sector drawdowns hit everything in it.

BBP Holdings

As of Aug 19, 2026, 3:00 AM
Asset class
Stocks
Holdings
198
Top-10 weight
21%
Largest holding
CRNX3.1%

Sectors

  • Health Care100.0%

Geography

  • United States86.10%
  • United Kingdom4.97%
  • Switzerland3.11%
  • China1.89%
  • Denmark1.43%
  • Germany1.27%
The fund’s holdings, weight-ordered — page 1 of 2.
#TickerCompanyWeight %SharesMarket valueIn ETFs
001CRNXCrinetics Pharmaceuticals Inc3.10%—$3M80
002OMEROmeros Corp2.50%—$3M48
003VSTMVerastem Inc2.20%—$2M42
004IOVAIovance Biotherapeutics Inc2.19%—$2M69
005KNSAKiniksa Pharmaceuticals International Plc1.92%—$2M64
006ZLABZai Lab Ltd1.89%—$2M15
007HALOHalozyme Therapeutics Inc1.87%—$2M167
008PGENPrecigen Inc1.85%—$2M56
009PTGXProtagonist Therapeutics Inc1.82%—$2M117
010ACADACADIA Pharmaceuticals Inc1.73%—$2M114
011BGNEBeOne Medicines Ltd1.73%—$2M1
012GERNGeron Corp1.68%—$2M50
013NUVBNuvation Bio Inc1.66%—$2M63
014REGNRegeneron Pharmaceuticals Inc1.66%—$2M321
015INSMInsmed Inc1.65%—$2M153

Showing 1–15 of 30 holdings

BBP Performance

Shows how $10,000 changes over the selected period, with cash distributions reinvested at the closing price on each ex-dividend date.

Performance data is unavailable.

Returns run to the last market close, with cash distributions reinvested. Each period starts on the same date that many months or years earlier. Periods over one year show the average yearly return.

Trailing total return for BBP. Periods over one year show the average yearly return.
PeriodBBP
Year to dateHistory unavailable—
1 monthHistory unavailable—
3 monthsHistory unavailable—
1 yearHistory unavailable—
3 yearsHistory unavailable—per year
5 yearsHistory unavailable—per year
10 yearsHistory unavailable—per year

Calendar-year total return with cash distributions hypothetically reinvested at the ex-dividend date’s closing price. The current year shows year to date.

Annual return data is unavailable.

BBP in the news

ETF.net Research hasn’t filed on BBP yet — coverage lands here as it’s written.

BBP Dividends

Adds up every distribution paid per share over the last 12 months, divided by the last completed close. Distributions are counted by ex-date.
Data unavailableLast 12 months
Payout per share
Data unavailableLast 12 months

Distribution data unavailable.

BBP Risk

How much the fund’s monthly returns vary, scaled to a year.
—
No data available
How it’s calculated: standard deviation

The sample standard deviation of monthly total returns, multiplied by the square root of 12.

Uses up to 36 complete months, with at least 12 required. Total returns include reinvested distributions.

Return above 3-month US Treasury bills per unit of volatility.
—
No data available
How it’s calculated: Sharpe ratio

Subtract each month’s Treasury-bill return from the fund’s monthly total return.

Divide the average of those excess returns by their sample standard deviation, then multiply by the square root of 12.

Uses up to 36 complete months, with at least 12 required. Each month uses the Treasury yield quoted at the end of the previous month.

The largest fall from a peak to the low that followed.
—
No data available
How it’s calculated: maximum drawdown

The largest percentage decline from an earlier peak, using total returns with reinvested distributions.

Uses up to five years through the last close, with at least 12 months required.

How strongly the fund’s returns move with its asset-class index.
0.87
vs its asset-class index
How it’s calculated: beta

The beta figure is supplied by FMP. The comparison index depends on the fund’s broad asset class.

BBP Cost

Expense Ratio
0.34%